abexxa

News

Boehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area in the space of a year.

News

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.